ImmunoGen Beats Up on Analysts Yet Again
ImmunoGen (NAS: IMGN) reported earnings on Jan. 27. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q2), ImmunoGen crushed expectations on both revenues and earnings per share.
Compared to the prior-year quarter, revenue increased significantly and GAAP earnings per share shrank.
Margins increased across the board.
Immunogen tallied revenue of $7.6 million. The six analysts polled by S&P Capital IQ expected to see revenue of $5.4 million. Sales were 82% higher than the prior-year quarter's $4.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.
EPS came in at -$0.17. The six earnings estimates compiled by S&P Capital IQ predicted -$0.23 per share. GAAP EPS were -$0.17 for Q2 compared to -$0.21 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.
For the quarter, gross margin was 100%, 38,310 basis points better than the prior-year quarter. Operating margin was -167.7%, 20,360 basis points better than the prior-year quarter. Net margin was -167.4%, 17,330 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $6.5 million. On the bottom line, the average EPS estimate is -$0.22.
Next year's average estimate for revenue is $21.3 million. The average EPS estimate is -$0.95.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 270 members out of 290 rating the stock outperform, and 20 members rating it underperform. Among 79 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 76 give ImmunoGen a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ImmunoGen is outperform, with an average price target of $15.40.
The biotechnology and health-care investing landscape is littered with also-rans and a few major winners. Is ImmunoGen the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Immunogen to My Watchlist.
At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.